Knight Capital Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Knight Capital Group’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$38K	Buy	+4,113	New	+$52.8K	﹤0.01%	3097

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Knight Capital Group's CASC Position: Q2 2013 in Review

Knight Capital Group opened a new position in Cascadian Therapeutics, Inc. (CASC) in Q2 2013: 4,113 shares worth $38K. The stake represents ﹤0.01% of the portfolio and ranks #3097 among its holdings.

66 funds tracked by Wall St. Rank hold CASC as of Q2 2013.

Knight Capital Group held 4,113 shares of Cascadian Therapeutics, Inc. worth $38K as of Q2 2013.
Cascadian Therapeutics, Inc. was a new Knight Capital Group position in Q2 2013.
Cascadian Therapeutics, Inc. made up ﹤0.01% of Knight Capital Group's portfolio in Q2 2013, its #3097 holding.
66 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.